13 patents
Utility
Generation of Binding Molecules
25 May 23
Provided are methods for efficiently and comprehensively screening antibody repertoires from B cells to obtain and produce molecules with binding characteristics and functional activities for use in human therapy.
Mark THROSBY, Ton LOGTENBERG, John DE KRUIF
Filed: 5 Aug 22
Utility
Binding Molecules That Modulate a Biological Activity Expressed by a Cell
14 Oct 20
The invention provides means and methods for inhibiting a biological activity of cells.
Cecilia Anna Wilhelmina GEUIJEN, Rinse KLOOSTER, Cornelis Adriaan DE KRUIF, Paulus Johannes TACKEN, Mark THROSBY, Ton LOGTENBERG
Filed: 5 Jul 18
Utility
Antibody Producing Non-human Animals
7 Oct 20
Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is a common human, human-like, or humanized light chain.
Ton Logtenberg, Mark Throsby, Robert A. Kramer, Rui Daniel Pinto, Cornelis A. De Kruif, Erwin Houtzager
Filed: 18 Jun 20
Utility
Antibodies for the Treatment of ERBB-2/ERBB-3 Positive Tumors
16 Sep 20
The invention relates to the field of antibodies.
Mark THROSBY, Cecillia Anna Wilhelmina GEUIJEN, David Andre Baptiste MAUSSANG-DETAILLE, Ton LOGTENBERG
Filed: 2 Apr 18
Utility
Generation of Binding Molecules
5 Aug 20
Provided are methods for efficiently and comprehensively screening antibody repertoires from B cells to obtain and produce molecules with binding characteristics and functional activities for use in human therapy.
Mark THROSBY, Ton LOGTENBERG, John DE KRUIF
Filed: 16 Apr 20
Utility
Antibodies That Bind Egfr and Cmet
5 Aug 20
The invention as disclosed herein relates to bispecific antibodies that comprises a first variable domain that can bind an extracellular part of epidermal growth factor receptor (EGFR) and a second variable domain that can bind an extracellular part of MET Proto-Oncogene, Receptor Tyrosine Kinase (cMET).
Cecilia Anna Wilhelmina GEUIJEN, Robertus Cornelis ROOVERS, Mark THROSBY, Cornelis Adriaan De Kruif, Ton Logtenberg
Filed: 8 Aug 18
Utility
Bispecific Anti PD1-ANTI TIM3 Antibodies
8 Jul 20
The disclosure provides means and methods for interfering with Programmed Cell Death 1 protein (PD-1) and T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) mediated inhibition in a PD-1 and/or TIM-3 positive cell.
Cecilia Anna Wilhelmina GEUIJEN, Rinse KLOOSTER, Cornelis Adriaan DE KRUIF, Paulus Johannes TACKEN, Mark THROSBY, Ton LOGTENBERG
Filed: 5 Jul 18
Utility
Antibodies That Modulate a Biological Activity Expressed by a Cell
8 Jul 20
The invention provides means and methods for interfering with Programmed Cell Death 1 protein (PD-1) and Lymphocyte activation 3 (LAG 3) mediated inhibition in a PD-1 and/or LAG3 positive cell.
Cecilia Anna Wilhelmina GEUIJEN, Rinse KLOOSTER, Cornelis Adriaan DE KRUIF, Paulus Johannes TACKEN, Mark THROSBY, Ton LOGTENBERG
Filed: 5 Jul 18
Utility
ERBB-2 and ERBB3 Binding Bispecific Antibodies for Use In the Treatment of Cells That Have an NRG1 Fusion Gene
1 Apr 20
The invention relates to the field of antibodies.
Mark THROSBY, Cecilia Anna Wilhelmina GEUIJEN, David Andre Baptiste MAUSSANG-DETAILLE, Ton LOGTENBERG
Filed: 2 Apr 18
Utility
Binding Molecules That Modulate a Biological Activity Expressed by a Cell
15 Jan 20
The invention provides means and methods of stimulating activity of a member of the TNF receptor superfamily on a cell.
Cecilia Anna Wilhelmina GEUIJEN, Mark THROSBY, Cornelis Adriaan DE KRUIF, Rinse KLOOSTER, Paulus Johannes TACKEN, Ton LOGTENBERG
Filed: 21 Sep 17
Utility
Methods and Means for the Production of Ig-like Molecules
15 Jan 20
The invention provides means and methods for producing one or more Ig-like molecules in a single host cell.
Cornelis Adriaan DE KRUIF, Linda Johanna Aleida Hendriks, Ton Logtenberg
Filed: 19 May 19
Utility
Bispecific Igg Antibodies As T Cell Engagers
20 Nov 19
Bispecific IgG antibodies which bind to CLEC12A and an antigen on an immune effector cell are provided.
Alexander Berthold Hendrik Bakker, Pieter Fokko Van Loo, Ton Logtenberg
Filed: 18 Apr 19
Utility
Multivalent Antibody
20 Nov 19
The invention relates to a multivalent antibody which comprises: a base antibody portion which comprises two binding domains; and at least one additional binding domain, wherein the base antibody portion is connected by a linker to the at least one additional binding domain, wherein each binding domain of the base antibody portion and each of the at least one additional binding domains all have a common variable region, and wherein the linker comprises a hinge sequence or a sequence derived from a hinge sequence.
Cornelis Adriaan de Kruif, Linda Johanna Aleida Hendriks, Ton Logtenberg
Filed: 28 Mar 19
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first